Trial Profile
A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Adalimumab
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS
- Sponsors Novartis Pharmaceuticals
- 15 Nov 2023 Results of subgroup analysss evaluating the effect of SEC and SDZ-ADL on spinal radiographic progression in patients based on the presence of syndesmophytes and elevated high-sensitivity CRP (hsCRP) levels at BSL, presented at the ACR Convergence 2023
- 03 Jun 2023 Results of Subgroup Analyses evaluating the effect of SEC and SDZ-ADL on spinal radiographic progression in subgroups of pts based on the presence of syndesmophytes and elevated high-sensitivity CRP (hsCRP) levels at BSL, presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results assessing effect of SEC vs adalimumab biosimilar (SDZ-ADL) on spinal radiographic progression from SURPASS,[2,3] the first head-to-head study in r-axSpA presented at the 24th Annual Congress of the European League Against Rheumatism